Source:http://linkedlifedata.com/resource/pubmed/id/19954816
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-2-17
|
| pubmed:abstractText |
The increased expression of PDZ binding kinase/lymphokine-activated killer T-cell-originated protein kinase (PBK/TOPK) is associated with some human malignant tumors. In this study, we analyzed PBK/TOPK expression in hepatic primary tumor and explored its role in cholangiocarcinoma biology. Seventy-four cholangiocarcinomas, 33 hepatocellular carcinomas, and 10 normal liver tissues were prepared from paraffin-embedded specimens. PBK/TOPK protein was assessed by immunohistochemical staining, and the survival time was analyzed with the Kaplan-Meier method. The protein, mRNA of PBK/TOPK, and cell cycle of cholangiocarcinoma cell line after PBK/TOPK suppression with small interfere RNA were studied by Western blot, semiquantitative reverse transcriptase-polymerase chain reaction, and flow cytometry, respectively. PBK/TOPK was usually expressed in normal bile duct epithelial cells and much more frequently expressed in cholangiocarcinoma (68/74) but never expressed in hepatocytes and hepatocellular carcinomas (0/33). PBK/TOPK down-regulation was related to the poor prognosis of patients with cholangiocarcinoma (P = .013). Epidermal growth factor can enhance PBK/TOPK expression in cholangiocarcinoma QBC 939 cells, but suppression of PBK/TOPK in the cells did not affect their proliferation. PBK/TOPK protein could serve as a useful indicator for histopathologic differentiation between cholangiocarcinoma and hepatocellular carcinomas and the low expression of PBK/TOPK is predicative of poor survival in cholangiocarcinoma patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1532-8392
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2010 Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
41
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
415-24
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:19954816-Adult,
pubmed-meshheading:19954816-Aged,
pubmed-meshheading:19954816-Bile Ducts,
pubmed-meshheading:19954816-Blotting, Western,
pubmed-meshheading:19954816-Carcinoma, Hepatocellular,
pubmed-meshheading:19954816-Cell Cycle,
pubmed-meshheading:19954816-Cell Line, Tumor,
pubmed-meshheading:19954816-Cells, Cultured,
pubmed-meshheading:19954816-Cholangiocarcinoma,
pubmed-meshheading:19954816-Diagnosis, Differential,
pubmed-meshheading:19954816-Epithelial Cells,
pubmed-meshheading:19954816-Female,
pubmed-meshheading:19954816-Flow Cytometry,
pubmed-meshheading:19954816-Gene Silencing,
pubmed-meshheading:19954816-Humans,
pubmed-meshheading:19954816-Immunohistochemistry,
pubmed-meshheading:19954816-Kaplan-Meier Estimate,
pubmed-meshheading:19954816-Liver Neoplasms,
pubmed-meshheading:19954816-Male,
pubmed-meshheading:19954816-Middle Aged,
pubmed-meshheading:19954816-Prognosis,
pubmed-meshheading:19954816-Proportional Hazards Models,
pubmed-meshheading:19954816-Protein-Serine-Threonine Kinases,
pubmed-meshheading:19954816-RNA, Messenger,
pubmed-meshheading:19954816-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:19954816-Sex Factors
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
|
| pubmed:affiliation |
State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
|
| pubmed:publicationType |
Journal Article
|